Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | +21.21% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.78 | N/A | +21.21% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions affecting performance. They maintained a focus on long-term goals, but provided no new guidance.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current setbacks.
No specific updates on product pipeline were provided.
PTC Therapeutics reported a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue data and forward guidance may raise concerns among investors about the company's short-term outlook. The stock reaction suggests that investors are cautious about the company's current performance and future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
H WORLD GROUP LIMITE ADR
Mar 14, 2017